Real-world data: Clinical characteristics and outcomes of patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab in Veteran Health Administration.

Authors

Munaf Alkadimi

University of Texas Health Science Center at San Antonio, San Anonio, TX

Munaf Alkadimi , Kana Lucero , Lauren Diaz Boyle , Maria Elena Fierro , Kathleen Franklin , Zohra Nooruddin , Michael Mader

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Application of the albumin-bilirubin (ALBI) grade as predictive marker of atezolizumab plus bevacizumab (A+B) treatment outcomes for patients with advanced hepatocellular carcinoma (HCC): Real-world retrospective analysis at Veterans Health Administration (VHA).

First Author: Munaf Alkadimi

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

A single-center, real-world experience of atezolizumab plus bevacizumab as first-line therapy in patients with unresectable hepatocellular carcinoma, including patients with advanced cirrhosis.

First Author: Jay Parekh

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Individual patient-level data validation of surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma: Post-hoc analysis of IMbrave150 and real-world observations.

First Author: Mir Lim

insert_chart_outlined

Poster

2023 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Efficacy and safety of frontline systemic therapy for advanced hepatocellular carcinoma (aHCC): A network meta-analysis of landmark phase III trials.

First Author: Claudia A.M. Fulgenzi